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Abstract 
Background. Epigenetic variation is a main regulation mechanism of gene expression in various cancer 
histotypes, and due to its reversibility, the potential impact in therapy can be very relevant. Methods. 
Based on a selected pair, breast cancer (BC) and melanoma, we conducted inference analysis in parallel 
on a few cell lines (MCF-7 for BC and A375 for melanoma). Starting from differential expression 
after treatment with a demethylating agent, the 5-Aza-2'-deoxycytidine (DAC), we provided pathway 
enrichment analysis and gene regulatory maps with cross-linked microRNAs and transcription factors. 
Results. Several oncogenic signaling pathways altered upon DAC treatment were detected with 
significant enrichment. We represented the association between these cancers by depicting the landscape 
of common and specific variation affecting them.    
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Introduction 
Recent advances in the field of epigenetics have provided new insights on the global 
epigenetic modifications that promote cancer development and progression [1,2]. Notably, 
epigenetic therapy, which is a consequence of the reversible nature of the epigenetic changes that 
alter gene expression in many tumor histotypes [3, 4], is the ultimate interest of many proposed 
research projects, including the present one. Among several drugs with anti-tumorigenic effect 
regulating the epigenetic status of cells, 5-Aza-2'-deoxycytidine (DAC, Dagogen) is a potent 
demethylating agent known for anti-leukemic effect in the mouse model [5, 6]. DAC acts to 
correct epigenetic defect including reactivation of tumor suppressor genes (TSG) [7] silenced by 
epigenetic mechanisms in tumor tissues [2]. Combining DAC with a chemotherapeutic agent 
(Carboplatin) in patients with recurrent, platinum-resistant, Epithelial Ovarian Cancer (EOC), 
was shown to exert a potent demethylating effect justifying the need of further testing for clinical 
efficacy [8]. The DAC effect was evaluated in breast cancer (BC) cell lines by gene expression 
analysis: at the used concentrations, there is a role appearing for treatment in different cellular 
processes linked to TNF-α-dependent apoptosis [9]. Also, the safety of DAC combined with 
chemotherapy in metastatic melanoma was reported in [10]. 
 Rationale for the association between BC and melanoma, is provided first of all by evidence: 
genetic relationships and common variant genes appeared in [11, 12, 13]; a high risk association 
of melanoma in BC patients was reported in [14]; this risk holds especially for patients not 
receiving anti-estrogen therapy [15]; several biomarkers have been proposed to identify cancer 
stem cells in these two tumors [16].  In general, risk factors such as family history play a role in 
both cancers. Moreover, carriers of mutations in BRCA2 - the BC predisposition gene - have an 
increased risk of melanoma, while carriers of mutations in the melanoma susceptibility gene - 
CDKN2A - exhibit a higher than expected risk of BC. We therefore hypothesized that pathways 
involved in the development of both cancers may to a certain extent overlap, and that survivors 
of one cancer may be prone to develop the other one. Specifically, epigenetic mechanisms which 
sum to mutations during cancer progression, can be explored through pathways that are in 
common between the two cancers and result up-regulated after DAC treatment. 
Our goal is to investigate DAC treatment effects in MCF-7 (BC) and A375 (melanoma) cell 
lines. We elucidate pathway landscapes and regulatory networks following gene expression 
profiling and aimed to identify epigenetically modified genes. Once the functionally enriched 
pathways are identified, both transcriptional and post-transcriptional regulatory networks are 
derived with the ultimate goal of assigning to them a role of possible drivers of future 
developments in novel anticancer target therapies. The sections of the paper are organized into 
Methods, Results, and Discussion at the end. 
 
Methods 
 
Microarray Analysis.  
The MCF-7 and A375 cell lines were cultured in DMEM medium supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, at split ratio of 1:4 twice a week. After 24 hours of spit the 
culture medium was changed with media containing 2,5 µM 5-Aza-2-dC (DAC). 5-aza-2’-
deoxcytidine (Sigma) was prepared freshly prior of experiments as a 10 mM stock solution 
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diluted in acetic acid: water (1:1). The treated cells were collected after 48 hours and the mRNA 
was extracted for pelleted cells. The steps for cDNA microarray analysis were mainly two: 1. 
Total RNA samples were isolated from treated/untreated cells using TRIZOL reagent 
(Invitrogen); 2. Concentration of purified RNA samples were determined by A260 measurement 
and the quality was checked by Lab-on-a-chip analysis (total RNA nano biosizing assay, Agilent) 
with the Agilent 2100 Bioanalyzer RNAs isolated from different tumor tissues, and transcribed in 
cDNAs, were used to carry out the analysis. The cDNAs from treated BC were labeled with cy5 
red fluorescent dye and untreated BC with cy3 green fluorescent dye. Hybridization was done on 
a microarray chip called MWG Human Cancer Array containing 50-mer oligo probes for 1920 
genes (1853 human genes associated with cancer, 27 control genes and 40 replicated genes). 
Spots of fluorescence intensity were read by dual laser scanner (BioDiscovery) and the values 
were processed with Mavi Pro-2.6.0. (MWG Biotech), by computing background subtraction, 
normalization to a number of housekeeping genes, and comparison with untreated cancers. In 
order to select deregulated genes, we considered the cy5/cy3 normalized ratio (NR), calculated 
for each gene and by taking the ratio of the intensity in cy5 (Ic5) and the normalized intensities 
in cy3 (nIc3). Then, to reduce variability, all ratio values were transformed in log base 2. For 
inclusion of highly deregulated genes, we considered as up-regulated or down-regulated genes 
those with log2 (NR) > 2.0 and log2 (NR) < -2.0, respectively. 
 
Functional Enrichment and Pathways Analysis.  
The analysis of the list of the significantly deregulated genes is based on the F-Census database 
[17] (http://bioinfo.hrbmu.edu.cn/fcensus/Home.jsp) in order to extract information from highly 
inconsistent cancer gene data sources including CGC (Cancer Gene Census), OMIM (Online 
Mendelian Inheritance in Man), AGCOH(Atlas of Genetics and Cytogenetics in Oncology and 
Haematology), CancerGenes, TSGDB (Tumor Suppressor Gene Database), TGDBs (Tumor 
Gene Family Databases), two lists (H-list and R-list) that report genes deregulated in cancer 
samples and identified by mutational screens of cancer genomes using high-throughput 
techniques, and post-transcriptional regulation predicted by some microRNA (miRNA) target 
prediction algorithms, including TargetScan, PicTar, DIANA-microT and MirTarget2. For 
bioinformatics and functional annotation, we used over-representation analysis (ORA), available 
in ConsensusPathDB [18] (http://cpdb.molgen.mpg.de/), and aimed at identifying the functional 
categories and biological pathways among the differentially expressed (DE) genes between 
treated and untreated cell lines in both cancers. ORA allows interactive querying to perform a 
functional enrichment (FE) from comparison of two lists of genes (deregulated genes versus the 
universe, i.e. the human genome). The output links the genes to the corresponding annotations, 
found in databases, i.e. KEGG, Biocarta, Reactome, wikipathways. Among these examples, the 
ConsensusPathDB latest version – release 26 - was used. 
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Transcriptional and Post-transcriptional Regulatory Network Analysis. The detection of 
Transcription Factors (TFs) predicted to regulate the list of significantly deregulated genes upon 
DAC treatment in BC, was performed using TFactS [19] (http://www.tfacts.org/). TFactS DB 
contains genes responsive to TFs, according to experimental evidence reported in literature, and 
reports two datasets: (i) A sign-sensitive catalogue that indicates the type (up/down) of TF 
regulation exerted on its targets; (ii) A sign-less catalogue that includes all regulatory interactions 
contained in sign sensitive and further interactions without the specific type of regulation. 
TFactS takes as a query the two lists of up-/down-regulated genes and compares them with sign-
sensitive catalog of manually curated annotated target genes, then returning the lists of activated 
and inhibited TFs whose annotated target genes show a significant overlap with the query genes. 
 
We then merged the experimentally validated miRNA-target gene DBs: miRTarBase V.3.5 [20] 
(http://mirtarbase.mbc.nctu.edu.tw/), miRecords V.3 [21] (http://mirecords.biolead.org/), and 
miR2Disease [22] (http://www.mir2disease.org/), to build a non-redundant dataset of miRNA-
target genes regulatory (human) interactions. We used this consensus dataset to predict the 
miRNA regulators among the list of significantly deregulated genes. With Cytoscape [23] 
(http://www.cytoscape.org/) we showed the transcriptional and post-transcriptional regulatory 
networks whose analysis required a tool called “AdvancedNetworkMerged”, merging networks 
by set operations (union, intersection and difference). 
Results 
Pathway Signatures after DAC Treatment.  
Overall, we have identified 335 DE genes in BC, and 195 DE genes in melanoma upon DAC 
treatment of MCF-7 and A375 cell lines. In particular, we found 221 up-regulated genes in BC 
and 111 up-regulated genes in melanoma based on log2 (NR) > 2, with 29 genes in common. 
Then, we found 114 and 84 down-regulated genes based on log2 (NR) < -2 in BC and melanoma, 
respectively, with 50 down-regulated genes in common, and 13 genes down-regulated in 
melanoma and up-regulated in BC. We integrated the epigenetically modified genes with the F-
census database (Additional Table 1) and the information about their methylation state when 
available from previous work [24] centered on DNA methylation profiling in MCF-7 (Additional 
Table 2). The Additional file 1 reports the list of all the Additional Tables, and the Additional 
Figure 1. The following examples are listed as top up-regulated genes in BC (Additional Table 
1): 
CTAG1B (cancer/testis antigen 1B) - is a member of cancer/testis (CT) antigens found expressed 
in normal testis and in many cancers [25, 26]. We found CTAG2 up-regulated in BC, but down-
regulated in melanoma. Thanks to the capacity of a subset of these antigens to activate a 
spontaneous cellular immune responses in cancer patients [27], they are ideal cancer antigen 
targets for tumor immunotherapy, especially for BC after DAC treatment as with adult T-cell 
leukemia/lymphoma (ATLL) [28]; 
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RAB30 - is a member of Ras-associated binding proteins (Rabs), which are involved in 
regulating different steps during exocytosis [29]. In particular, Rab30 is Golgi-specific Rabs, 
required for the structural integrity of the Golgi apparatus [30], and it was found hypomethylated 
in MCF7, together with other up-regulated genes (Additional Table 2); 
MAGEA1 and MAGEB2 - are members of CT antigens; in particular, MAGEA1 was found 
expressed in 10% of cancer cells in conjunctival melanomas [31], and could be another candidate 
working in combination with immunotherapy; 
FHL2-  is a member of the four-and-a-half-LIM-only protein family, found over-expressed in 
BC cell lines upon DAC [32]; it can inhibit the proliferation and invasive growth of human 
breast cancer cells by repressing the functional activity of an inhibitor of DNA binding 3 (ID3) 
[33]. 
 
The following examples are listed as top up-regulated genes in melanoma (Additional Table 1): 
S100A2 - is an EF hand calcium binding protein A2, given that the S100 gene family includes at 
least 13 members that are involved in the regulation of a number of cellular processes such as 
cell cycle progression and differentiation. It is a potential biomarker in several cancers including 
melanoma and BC, and may have a tumor suppressor function [34]. Its expression is stimulated 
by Jun transcription factor which was found up-regulated upon DAC treatment in both cancers; 
IGF2 (insulin-like growth factor 2) - is up-regulated in BC. It was recently shown that the 
epigenetic alterations of IGF-2 are associated with development and progression of 
hepatocellular carcinoma (HCC) [35]; 
FANCA (Fanconi anemia, complementation group A) - mutations in this gene represent the most 
common cause of Fanconi anemia. There are 15 known Fanconi anemia genes involved in 
different pathways that coordinate multiple DNA repair [36]. 
The following genes commonly down-regulated in both cancer cell lines after DAC were found: 
CDKN2B - is a cyclin-dependent kinase inhibitor 2B (known also as p15, and it inhibits CDK4) 
and a key regulator of biological processes repressing cell cycle progression by inhibition of 
cdk4 and cdk6 [37]. This gene is known as a melanoma susceptibility gene and mutations carrier 
in CDKN2A, correlated with a higher risk of BC. Since down-regulation upon DAC treatment 
results in both cancer cell lines, it may represent a side effect of treatment. The balance between 
DNA methylation and demethylation is a critical regulator of the methylation status of cyclin-
dependent kinase inhibitor [38]. In fact, it is known that the demethylating agents function as 
DNA methyltransferase inhibitors, can be incorporated into the genome during DNA replication, 
and bind DNA methyltransferases that have the catalytic domain. This may lead to global 
hypomethylation and re-expression of both tumor suppressor genes and proto-oncogenes 
misregulation [39]; 
 
CDH6 (cadherin 6) - is a membrane glycoprotein and a member of the cadherin superfamily type 
II involved in cell-cell adhesion, differentiation and morphogenesis. The aberrant expression of 
cadherin-6 correlates with a poor prognosis in patients with E-cadherin-absent Renal cell 
carcinomas (RCC) and could be a useful tool to estimate the malignancy potential [40]; 
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CDH7 (cadherin 7) - is another member of the cadherin superfamily type II. It was shown that 
CDH7 plays a role in tumor development of malignant melanoma cells by interacting with 
melanoma inhibitory activity protein (MIA) and migration melanoma cell [41]. 
 
The top down-regulated genes in the A375 cell line are listed below: 
BAI1 (brain-specific angiogenesis inhibitor 1) - is a tumor suppressor gene and transmembrane 
protein with anti-angiogenic and antiproliferative activity [42]; 
 
FKSG2 - is a tumor protein, translationally-controlled 1 pseudogene, which we found down- 
regulated in BC too. 
We found discrepancy in the regulation of some genes upon DAC treatment, with evidence of 
genes down-regulated in melanoma and up-regulated in BC. Examples worth of explanation are 
the following: 
1. CFLAR - is a CASP8 and FADD-like apoptosis regulator, and structurally similar to 
caspase-8. It is found expressed in pulmonary metastases in osteosarcoma patients and 
human xenografts [43]. Its down-regulation contributes to apoptosis in human lung 
cancer cells, suggesting that its targeting may represent a promising therapeutic strategy 
for the cancer patients with over-expression of this gene [44]; 
2. MDM2 (Mouse double minute 2) - is an oncogene E3 ubiquitin protein ligase, regulated 
by p53 in case of DNA damage and part of an autoregulatory negative feedback loop 
[45]; 
3. PRKCH (protein kinase C, eta) - is a calcium-independent and phospholipids-dependent 
protein kinase. It is mostly expressed in epithelial tissues and has been shown to activate 
the protein kinase cascade that targets CCAAT/enhancer-binding protein alpha (CEBPA), 
following the same expression as PRKCH in both cancer cell lines [46]. 
Using ORA from the consensusPathDB, we found a list of over-represented functional categories 
and pathways referring to up- and down-regulated genes in the cancer cell lines. The enriched 
pathways are reported in Additional Table 3. The graphical tool in consensusPathDB was used to 
select the most interesting pathways involved in up- and down-regulated genes (Figure 1 and 
Figure 2). The node size indicates the size of the gene set; the node color corresponds to the p-
value (deeper red means smaller p-value); the edge color represents the number of shared genes 
in the predefined dataset; the color node border indicates the common pathways among 
genetically regulated genes. In Figure 1 and Figure 2 we show the common pathways regulated 
upon DAC treatment; in Table 1 we report the common enriched pathways among up-regulated 
genes. 
The commonly enriched pathways associated to up-regulated genes is ATM signaling (Ataxia 
telangiectasia mutated) which is associated with the activation of p73, a member of the p53 
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tumor suppressor family regulating cell cycle and apoptosis after DNA damage, and found 
inactivated in many tumor histotypes [47,48]. The methylation status of p73 was shown to be 
common in patients with MDS and associated with poor prognosis [49]. p73 plays also a key role 
in p53 signaling pathway exerting an anticarcinogenic effect [50]; the activation of this signaling 
pathway induced by a natural diterpenoid compound was associated to G(2)/M cell cycle arrest 
in human melanoma cells to repair DNA damage. Similarly, such mechanism could be activated 
here, due to the up-regulation of genes involved in DNA repair (e.g. ATM is an important cell 
cycle checkpoint kinase). Then, evidence includes XPC that plays a central role in the 
recognition of DNA damage; LIG3 which is involved in excision repair; TDG which is important 
in DNA demethylation via the base excision repair pathway [51], in cellular defense against 
genetic mutation, in regulation of the epigenome and gene expression in non-melanoma skin 
cancer [52]; MUTYH that is involved in oxidative DNA damage repair in mammalian cells [53]. 
Another interesting pathways activated in both cancer cell lines is the extracellular matrix 
organization which involves up-regulation of different collagen genes like (COL1A1, COL1A2, 
COL3A1), and matrix metallopeptidase like (MMP8, MMP14). 
Table 2 lists the common pathways among down-regulated genes, and also the genes involved in 
each specific pathway. We found also Nuclear receptor transcription pathway enriched among 
down-regulated genes like NR1D1, which is a member of the nuclear receptor subfamily 1, also 
found expressed in human endometrial stromal and epithelial cells [54]. 
In Table 3, we reported pathways that we found commonly enriched among up-regulated genes 
in one cancer cell line and down-regulated genes in the other cell line. The first example is the 
p53 signaling pathway, associated to up-regulated genes in MCF7. This is the case of PPM1D, a 
protein phosphatase, Mg2+/Mn2+ dependent, 1D, found over-expressed in different types of 
human tumors with poor prognosis, and negatively regulating p38 MAPK activity to reduce the 
phosphorylation of p53 [55, 56]. PPM1D could dephosphorylate ATM and MDM2 [57] involved 
in this pathway. Another key regulator in this pathway is TNFRSF10B (tumor necrosis factor 
receptor superfamily, member 10b), involved in apoptosis transduction [58]. Then, regulation of 
insulin-like growth factor (IGF) transport and uptake by IGFBPs that involves up-regulated 
genes in A375, e.g. IGF2 (insulin-like growth factor 2, also called somatomedin A), implicated in 
growth and development. It is known that epigenetic alterations of IGF2 is correlated with 
severity of hepatocellular carcinoma development and progression. Additionally, down-regulated 
genes are involved, e.g. MMP2, which is a metalloproteinase implicated in cancer progression 
and metastasis whose increase in expression is associated with a poor prognosis [59, 60]. 
Transcriptional and Post-transcriptional Regulatory Networks. 
We reported in Additional Table 4 the TFs that were found significantly enriched among the 
deregulated genes by using the TFactS analysis tool. We built with “AdvancedNetworkMerged” 
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in Cytoscape the union of transcriptional network and the miRNA regulatory network to show 
TFs and miRNAs experimentally validated as candidate regulators of the epigenetically modified 
genes in BC (Figure 3) and melanoma (Figure 4). Then, we extracted the sub-networks resulting 
from the intersection of the two regulatory networks (Figure 5).  
As a result, the epigenetic profile is described in an integrative network context. The symbols 
that we used are: node shape, indicating the physical entity (ellipse for epigenetically modified 
genes, Hexagon for TFs and Diamond for miRNAs); node color, indicating the differentially 
expressed genes; node border color, indicating the significant TFs enriched (with p-value<0.05) 
and obtained from the TFactS analysis, while the non-colored nodes correspond to TFs that 
regulate at least one target of the epigenetically modified genes. Then, the label color node 
reflects the presence of miR-family. The symbols in the Box below are used in the figures. 
 
In Figure 3, we reported the regulatory map of DE genes in MCF7. This network is composed by 
300 edges, 242 nodes that correspond to 66 up-regulated and 28 down-regulated genes, 67 
predicted TFs and 85 miRNAs. Among the predicted TFs, we found four - CEPBA, JUN, 
RUNX2 and ID2- that are up-regulated upon DAC treatment. In Figure 4, we reported the 
regulatory map of the epigenetically modified genes in A375 which is composed by 218 edges, 
173 nodes matching 28 up-regulated and 29 down-regulated genes, 53 predicted TFs and 66 
miRNAs. Among the predicted TFs we found three - CEPBA, JUN and AR- that are deregulated 
upon DAC treatment. In Figure 5, we reported the sub-network resulted from the intersection of 
the two regulatory networks in MCF7 and A375. This network is composed by 117 edges; 94 
nodes that correspond to 12 up-regulated, and 11 to down-regulated genes in both cells, while 4 
are up-regulated in BC and down-regulated in melanoma. Then, there are 41 predicted TFs and 
28 miRNAs. 
We found that the common up-regulated TF in both cell lines is JUN, a protoncogene that plays 
a dual role in regulation of tumor cell proliferation [61], and recently reported as candidate 
biomarker for personalized therapy in thymic epithelial tumors [62]. Its up-regulation is 
associated to the activation of IGF2 in both cell lines, and to an increased expression of MDM2 
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in MCF7. JUN represents a target of different miRNAs. For instance, miRNAs-15a/16 cluster, 
considered a tumor suppressor found deleted in different malignancies [63, 64], or miR-155 
reported as repressor of JUN in human dermal fibroblasts in vitro [65]. Interestingly, the up-
regulation of Jun TF in MCF7 is connected to the activation of TIMP1, a mettallopeptidase 
inhibitor whose overexpression contributes to antimetastatic effect in BC [66], and to the 
activation of NQO1 (NADPH quinone oxidoreductase 1), playing a cytoprotective role and 
found associated to increase cell-sensitivity to BC anticancer treatment [67]. 
An important JUN target is the SERPINB5 (serpin peptidase inhibitor clade B, member 5), 
found also up-regulated upon DAC treatment in MCF7, and known as an important suppressor of 
the invasion and migration of cancer cells [68]. Then, another target is STAT5B (signal 
transducer and activator of transcription 5B), a member of the STAT family of TFs, normally 
activated in response to cytokines and growth factors signals. It has been shown that the 
regulation of STAT1/STAT5 signalling pathway mediated by STAT5B is important in the 
regulation of essential functions in the mammary gland [69]. The TFact tool reported among the 
up-regulated target of STAT5B the DPAGT1 target, which is an enzyme that catalyzes 
glycoprotein biosynthesis and was found to be targeted also by wnt/β-Catenin signalling 
pathways, mediating a variety of critical developmental processes [70]. 
Another important key regulator is CEBPA, which is down-regulated in melanoma and up-
regulated in BC, a key TF involved in the regulation of cellular processes, especially in 
Hematopoietic system [71]. It was found epigenetically modified and post-transcriptionally 
regulated by miR-124 after DAC and trichostatin treatment in AML [72]. The repression of 
CEBPA by miR-138 was found to inhibit adipogenic differentiation of human adipose tissue-
derived mesenchymal stem cells [73]. The post-transcriptional mechanism of regulation may be 
the same also in both cancer cell lines (Figure 4). CEPBA, being up-regulated in MCF7, 
cooperates with RUNX2 (runt-related TF 2) to activate PTGS2 (prostaglandin-endoperoxide 
synthase 2). The latter is known as cyclooxygenase-2 (COX-2), an inducible enzyme responsible 
in the prostanoid biosynthesis and involved in inflammation and mitogenesis [74]. PTGS2 is a 
target for development of anticancer therapy, and the use of anti-inflammatory PTGS2 inhibitors 
represents a promising strategy in the treatment of solid tumors [75]. In the A375 cell line, the 
down-regulation of CEPBA could be responsible of the up-regulation of PSEN1 (presenilin 1), 
mutated in patient with sporadic early-onset Alzheimer's disease [76]. 
An important up-regulated gene in the A375 cell line is EZH2 (Enhancer of zeste homolog 2), a 
member of polycomb protein and a part of polycomb repressive complex, implicated in cancer 
stem cell maintenance and metastasis in breast and pancreatic cancer [77, 78], and it could be 
considered as a prognostic marker in renal cell carcinoma [79]. EZH2 is repressed by several 
miRNAs. It was reported in [80] that the loss of miR-101 expression correlates with the increase 
in EZH2 expression in invasive squamous cell carcinoma. 
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Discussion 
An accurate curation of pathway database with and regulatory relations was our preliminary step 
to draw a representative map of the major gene regulators and pathway landscapes involved in 
the DAC treatment of the MCF7 breast and the A375 melanoma cell lines. Then, a dissection of 
the key pathways and the knowledge of the interconnectivity between its components have been 
computed because conceived as valuable knowledge to gain towards new therapeutic approaches 
targeting the common genes involved in oncogenic pathways activated upon DAC treatment. 
Our results are in agreement with previous studies showing the mechanism underlying the 
anticancer effect of DAC treatment, and its involvement in activation of the ATM signaling 
pathways in cancer cell lines [81]. The identification of a potential TF-miRNA regulatory 
network contributes to shed light on the potential molecular mechanism played by DAC 
treatment in both cancer cells. It is important to notice that DAC could have a different effect in 
the regulation of key regulators depending on the cancer cell line. One of the controversial 
molecular mechanisms is the increase of CEBPA expression in MCF7 and its down-regulation in 
A375. However, its post-transcriptional regulation by miR-124 results affected by demethylating 
agent, suggesting that the effectiveness of epigenetic therapy already shown in AML could be 
further investigated in both the cancer cell lines examines here. 
Notably, some other interesting aspects are worth deeper discussion. The DAC treatment in 
MCF-7 and A375 cells induces down-regulation of different cytokines and interferons genes that 
represent key regulators of the cytokine-cytokine receptor interaction, Jak-STAT and PI3K-AKT 
signaling pathway, and they are associated to autoimmune thyroid disease. IL2RA and IL-2 are 
the common genes among all these pathways. The up-regulation of the interleukin-2 (IL-2) and 
its receptor alpha (IL2RA) are associated with the malignancy of the infiltrating human breast 
cancer. It may be the case that their down-regulation could produce an anticancer effect. The 
deregulation of these cytokines and interferons genes may suggest a potential role as breast 
cancer biomarker, or their possible use for novel DAC-combined treatments. 
All these evidences might help the design of new therapeutic formulations, and the identification 
of the best therapeutic combinations between the use of demethylating agent as DAC and 
immonotherapy, e.g directly targeting the CT antigens, the cancer antigens, or other therapeutic 
tools that could improve the anticancer effect of the demethylating agent, obtaining therefore 
more efficient BC therapy. Moreover, we are confident that gene expression and pathway 
signatures could give aid to the discovery of relevant connections among molecular mechanisms 
and drugs so as to significantly contribute to the improvement of drug for cancer therapy. As a 
follow up agenda for future research, we are planning to extend our analysis to other tumor 
histotypes, and also to use novel gene expression profiling (exploiting transcriptome landscapes 
from RNA-Seq) for refinement of pathway signatures. 
11 
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
ME participated in design of the study, performed the bioinformatic analysis and wrote the 
paper. DL carried out the microarray experiments. CC design and coordination of the study. 
EC design and coordination of the study and wrote the paper. All authors read and approved 
the final manuscript. 
 
Acknowledgements 
   The authors thanks the IWBBIO 2013 Special Issues’ Editors. 
Funding 
This work was supported by CNR, Pisa. MEB acknowledges partial support from the Flagship    
project InterOmics (PB.P05), funded by the Italian MIUR and CNR organizations. 
References 
1. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 2010, 31:27–36. 
2. Boumber Y, Issa J-PJ: Epigenetics in cancer: what’s the future? Oncol Williston Park N 2011, 25:220–226, 228. 
3. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37–
50. 
4. Grønbaek K, Hother C, Jones PA: Epigenetic changes in cancer. Apmis Acta Pathol Microbiol Immunol Scand 
2007, 115:1039–1059. 
5. Momparler RL: Epigenetic therapy of cancer with 5-aza-2’-deoxycytidine (decitabine). Semin Oncol 2005, 
32:443–451. 
6. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL: Enhancement of antineoplastic action 
of 5-aza-2’-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 2005, 16:301–308. 
7. Momparler RL, Bovenzi V: DNA methylation and cancer. J Cell Physiol 2000, 183:145–154. 
8. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE: A 
phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with 
recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010, 116:4043–4053. 
9. Kim JH, Kang S, Kim TW, Yin L, Liu R, Kim SJ: Expression profiling after induction of demethylation in 
MCF-7 breast cancer cells identifies involvement of TNF-α mediated cancer pathways. Mol Cells 2012, 
33:127–133. 
10. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, Lin Y, Christner S, Kirkwood JM: Safety 
and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and 
pharmacokinetic analysis. Ann Oncol Off J Eur Soc Med Oncol Esmo 2013, 24:1112–1119. 
12 
11. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Måsbäck A, Westerdahl J, Olsson H, Ingvar C: High 
frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive 
melanoma families. J Natl Cancer Inst 2000, 92:1260–1266. 
12. Debniak T, Scott RJ, Huzarski T, Byrski T, Masojć B, van de Wetering T, Serrano-Fernandez P, Górski B, 
Cybulski C, Gronwald J, Debniak B, Maleszka R, Kładny J, Bieniek A, Nagay L, Haus O, Grzybowska E, Wandzel 
P, Niepsuj S, Narod SA, Lubinski J: XPD common variants and their association with melanoma and breast 
cancer risk. Breast Cancer Res Treat 2006, 98:209–215. 
13. Debniak T, Scott R, Masojc B, Serrano-Fernández P, Huzarski T, Byrski T, Debniak B, Górski B, Cybulski C, 
Medrek K, Kurzawski G, van de Wetering T, Maleszka R, Kładny J, Lubinski J: MC1R common variants, 
CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer J Int Cancer 2006, 
119:2597–2602. 
14. Goggins W, Gao W, Tsao H: Association between female breast cancer and cutaneous melanoma. Int J 
Cancer J Int Cancer 2004, 111:792–794. 
15. Huber C, Bouchardy C, Schaffar R, Neyroud-Caspar I, Vlastos G, Le Gal F-A, Rapiti E, Benhamou S: 
Antiestrogen therapy for breast cancer modifies the risk of subsequent cutaneous melanoma. Cancer Prev Res 
Phila Pa 2012, 5:82–88. 
16. La Porta CAM, Zapperi S: Human breast and melanoma cancer stem cells biomarkers. Cancer Lett 2012. 
17. Gong X, Wu R, Zhang Y, Zhao W, Cheng L, Gu Y, Zhang L, Wang J, Zhu J, Guo Z: Extracting consistent 
knowledge from highly inconsistent cancer gene data sources. BMC Bioinformatics 2010, 11:76. 
18. Kamburov A, Stelzl U, Lehrach H, Herwig R: The ConsensusPathDB interaction database: 2013 update. 
Nucleic Acids Res 2013, 41(Database issue):D793–800. 
19. Essaghir A, Toffalini F, Knoops L, Kallin A, van Helden J, Demoulin J-B: Transcription factor regulation can 
be accurately predicted from the presence of target gene signatures in microarray gene expression data. 
Nucleic Acids Res 2010, 38:e120. 
20. Hsu S-D, Lin F-M, Wu W-Y, Liang C, Huang W-C, Chan W-L, Tsai W-T, Chen G-Z, Lee C-J, Chiu C-M, Chien 
C-H, Wu M-C, Huang C-Y, Tsou A-P, Huang H-D: miRTarBase: a database curates experimentally validated 
microRNA-target interactions. Nucleic Acids Res 2011, 39(Database issue):D163–169. 
21. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T: miRecords: an integrated resource for microRNA-target 
interactions. Nucleic Acids Res 2009, 37(Database issue):D105–110. 
22. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y: miR2Disease: a manually curated 
database for microRNA deregulation in human disease. Nucleic Acids Res 2009, 37(Database issue):D98–104. 
23. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T: Cytoscape 2.8: new features for data integration and 
network visualization. Bioinforma Oxf Engl 2011, 27:431–432. 
24. Li J, Gao F, Li N, Li S, Yin G, Tian G, Jia S, Wang K, Zhang X, Yang H, Nielsen AL, Bolund L: An improved 
method for genome wide DNA methylation profiling correlated to transcription and genomic instability in 
two breast cancer cell lines. Bmc Genomics 2009, 10:223. 
13 
25. Caballero OL, Chen Y-T: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 
2009, 100:2014–2021. 
26. Simpson AJG, Caballero OL, Jungbluth A, Chen Y-T, Old LJ: Cancer/testis antigens, gametogenesis and 
cancer. Nat Rev Cancer 2005, 5:615–625. 
27. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen Y-T, Old LJ: NY-ESO-1: 
review of an immunogenic tumor antigen. Adv Cancer Res 2006, 95:1–30. 
28. Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, 
Inagaki H, Old LJ, Ueda R, Sakaguchi S: Cancer/testis antigens are novel targets of immunotherapy for adult 
T-cell leukemia/lymphoma. Blood 2012, 119:3097–3104. 
29. Hutagalung AH, Novick PJ: Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev 
2011, 91:119–149. 
30. Kelly EE, Giordano F, Horgan CP, Jollivet F, Raposo G, McCaffrey MW: Rab30 is required for the 
morphological integrity of the Golgi apparatus. Biol Cell Auspices Eur Cell Biol Organ 2012, 104:84–101. 
31. Errington JA, Conway RM, Walsh-Conway N, Browning J, Freyer C, Cebon J, Madigan MC: Expression of 
cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human 
uveal and conjunctival melanoma. Br J Ophthalmol 2012, 96:451–458. 
32. Putnik M, Zhao C, Gustafsson J-Å, Dahlman-Wright K: Global identification of genes regulated by estrogen 
signaling and demethylation in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2012, 426:26–32. 
33. Chen Y-H, Wu Z-Q, Zhao Y-L, Si Y-L, Guo M-Z, Han W-D: FHL2 inhibits the Id3-promoted proliferation 
and invasive growth of human MCF-7 breast cancer cells. Chin Med J (Engl) 2012, 125:2329–2333. 
34. Naz S, Ranganathan P, Bodapati P, Shastry AH, Mishra LN, Kondaiah P: Regulation of S100A2 expression by 
TGF-β-induced MEK/ERK signalling and its role in cell migration/invasion. Biochem J 2012, 447:81–91. 
35. Dong Z, Yao D, Wu W, Qiu L, Yao N, Yan X, Yu D, Chen J: Correlation between epigenetic alterations in the 
insulin growth factor-II gene and hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi Zhonghua 
Ganzangbing Zazhi Chin J Hepatol 2012, 20:593–597. 
36. Kim H, Yang K, Dejsuphong D, D’Andrea AD: Regulation of Rev1 by the Fanconi anemia core complex. Nat 
Struct Mol Biol 2012, 19:164–170. 
37. Kim WY, Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265–275. 
38. Thillainadesan G, Chitilian JM, Isovic M, Ablack JNG, Mymryk JS, Tini M, Torchia J: TGF-β-dependent 
active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST 
complex. Mol Cell 2012, 46:636–649. 
39. Haaf T: The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: 
implications for methylation-associated cellular processes. Pharmacol Ther 1995, 65:19–46. 
40. Shimazui T, Kojima T, Onozawa M, Suzuki M, Asano T, Akaza H: Expression profile of N-cadherin differs 
from other classical cadherins as a prognostic marker in renal cell carcinoma. Oncol Rep 2006, 15:1181–1184. 
14 
41. Winklmeier A, Contreras-Shannon V, Arndt S, Melle C, Bosserhoff A-K: Cadherin-7 interacts with melanoma 
inhibitory activity protein and negatively modulates melanoma cell migration. Cancer Sci 2009, 100:261–268. 
42. Koh JT, Kook H, Kee HJ, Seo Y-W, Jeong BC, Lee JH, Kim M-Y, Yoon KC, Jung S, Kim KK: Extracellular 
fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking 
alphavbeta5 integrin. Exp Cell Res 2004, 294:172–184. 
43. Rao-Bindal K, Rao CK, Yu L, Kleinerman ES: Expression of c-FLIP in pulmonary metastases in 
osteosarcoma patients and human xenografts. Pediatr Blood Cancer 2013, 60:575–579. 
44. Wang Q, Sun W, Hao X, Li T, Su L, Liu X: Down-regulation of cellular FLICE-inhibitory protein (Long 
Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells. Cancer Cell Int 2012, 
12:54. 
45. Tang J, Agrawal T, Cheng Q, Qu L, Brewer MD, Chen J, Yang X: Phosphorylation of Daxx by ATM 
contributes to DNA damage-induced p53 activation. Plos One 2013, 8:e55813. 
46. Artemenko Y, Gagnon A, Aubin D, Sorisky A: Anti-adipogenic effect of PDGF is reversed by PKC 
inhibition. J Cell Physiol 2005, 204:646–653. 
47. Moll UM, Slade N: p63 and p73: roles in development and tumor formation. Mol Cancer Res Mcr 2004, 
2:371–386. 
48. La Sala D, Macaluso M, Trimarchi C, Giordano A, Cinti C: Triggering of p73-dependent apoptosis in 
osteosarcoma is under the control of E2Fs-pRb2/p130 complexes. Oncogene 2003, 22:3518–3529. 
49. Zhao Y, Fei C, Zhang X, Zhang Y, Guo J, Gu S, Li X, Chang C: Methylation of the p73 gene in patients with 
myelodysplastic syndromes: correlations with apoptosis and prognosis. Tumour Biol J Int Soc 
Oncodevelopmental Biol Med 2013, 34:165–172. 
50. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, Krammer PH, Melino G, Candi E: p73 
induces apoptosis by different mechanisms. Biochem Biophys Res Commun 2005, 331:713–717. 
51. Hashimoto H, Hong S, Bhagwat AS, Zhang X, Cheng X: Excision of 5-hydroxymethyluracil and 5-
carboxylcytosine by the thymine DNA glycosylase domain: its structural basis and implications for active 
DNA demethylation. Nucleic Acids Res 2012, 40:10203–10214. 
52. Ruczinski I, Jorgensen TJ, Shugart YY, Schaad YB, Kessing B, Hoffman-Bolton J, Helzlsouer KJ, Kao WHL, 
Wheless L, Francis L, Alani RM, Strickland PT, Smith MW, Alberg AJ: A population-based study of DNA repair 
gene variants in relation to non-melanoma skin cancer as a marker of a cancer-prone phenotype. 
Carcinogenesis 2012, 33:1692–1698. 
53. Raetz AG, Xie Y, Kundu S, Brinkmeyer MK, Chang C, David SS: Cancer-associated variants and a common 
polymorphism of MUTYH exhibit reduced repair of oxidative DNA damage using a GFP-based assay in 
mammalian cells. Carcinogenesis 2012, 33:2301–2309. 
54. Zenri F, Hiroi H, Momoeda M, Tsutsumi R, Hosokawa Y, Koizumi M, Nakae H, Osuga Y, Yano T, Taketani Y: 
Expression of retinoic acid-related orphan receptor alpha and its responsive genes in human endometrium 
regulated by cholesterol sulfate. J Steroid Biochem Mol Biol 2012, 128:21–28. 
15 
55. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV: The role of the 
MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. 
Oncogene 2007, 26:2502–2506. 
56. Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J, 
Hayashi Y: Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient 
survival. Cancer Sci 2011, 102:1101–1106. 
57. Lu X, Nguyen T-A, Moon S-H, Darlington Y, Sommer M, Donehower LA: The type 2C phosphatase Wip1: an 
oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008, 
27:123–135. 
58. Cabrol A, Desruennes M, Léger P: [Monitoring of patients with cardiac transplantation]. Ann Cardiol 
Angéiologie 1990, 39:607–612. 
59. Kondratiev S, Gnepp DR, Yakirevich E, Sabo E, Annino DJ, Rebeiz E, Laver NV: Expression and prognostic 
role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant 
melanomas. Hum Pathol 2008, 39:337–343. 
60. Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. 
Cell 2010, 141:52–67. 
61. Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859–868. 
62. Ma Y, Li Q, Cui W, Miao N, Liu X, Zhang W, Zhang C, Wang J: Expression of c-Jun, p73, Casp9, and N-ras 
in thymic epithelial tumors: relationship with the current WHO classification systems. Diagn Pathol 2012, 
7:120. 
63. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti 
L, Kipps T, Negrini M, Bullrich F, Croce CM: Frequent deletions and down-regulation of micro- RNA genes 
miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524–15529. 
64. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson JM, Cummins JM, Raymond 
CK, Dai H, Chau N, Cleary M, Jackson AL, Carleton M, Lim L: Transcripts targeted by the microRNA-16 
family cooperatively regulate cell cycle progression. Mol Cell Biol 2007, 27:2240–2252. 
65. Song J, Liu P, Yang Z, Li L, Su H, Lu N, Peng Z: MiR-155 negatively regulates c-Jun expression at the post-
transcriptional level in human dermal fibroblasts in vitro: implications in UVA irradiation-induced 
photoaging. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 2012, 29:331–340. 
66. Hassan ZK, Elamin MH, Daghestani MH, Omer SA, Al-Olayan EM, Elobeid MA, Virk P, Mohammed OB: 
Oleuropein induces anti-metastatic effects in breast cancer. Asian Pac J Cancer Prev Apjcp 2012, 13:4555–
4559. 
67. Sutton KM, Doucette CD, Hoskin DW: NADPH quinone oxidoreductase 1 mediates breast cancer cell 
resistance to thymoquinone-induced apoptosis. Biochem Biophys Res Commun 2012, 426:421–426. 
68. Chou R-H, Wen H-C, Liang W-G, Lin S-C, Yuan H-W, Wu C-W, Chang W-SW: Suppression of the invasion 
and migration of cancer cells by SERPINB family genes and their derived peptides. Oncol Rep 2012, 27:238–
245. 
16 
69. Evans MK, Yu C-R, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE: Expression of SOCS1 and 
SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and 
growth factor signals. Oncogene 2007, 26:1941–1948. 
70. Jamal B, Sengupta PK, Gao Z-N, Nita-Lazar M, Amin B, Jalisi S, Bouchie MP, Kukuruzinska MA: Aberrant 
amplification of the crosstalk between canonical Wnt signaling and N-glycosylation gene DPAGT1 promotes 
oral cancer. Oral Oncol 2012, 48:523–529. 
71. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Interleukin-2 and its receptor complex 
(alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical 
comparative study. Breast Cancer Res Bcr 2004, 6:R1–7. 
72. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen S-S, Blagitko-Dorfs N, Maharry K, Whitman SP, 
Schmittgen TD, Lübbert M, Marcucci G, Bloomfield CD, Plass C: Epigenetic modification of CCAAT/enhancer 
binding protein alpha expression in acute myeloid leukemia. Cancer Res 2008, 68:3142–3151. 
73. Yang Z, Bian C, Zhou H, Huang S, Wang S, Liao L, Zhao RC: MicroRNA hsa-miR-138 inhibits adipogenic 
differentiation of human adipose tissue-derived mesenchymal stem cells through adenovirus EID-1. Stem Cells 
Dev 2011, 20:259–267. 
74. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu 
Rev Biochem 2000, 69:145–182. 
75. Méric J-B, Rottey S, Olaussen K, Soria J-C, Khayat D, Rixe O, Spano J-P: Cyclooxygenase-2 as a target for 
anticancer drug development. Crit Rev Oncol Hematol 2006, 59:51–64. 
76. Kim J, Bagyinszky E, Chang YH, Choe G, Choi B-O, An SSA, Kim S: A novel PSEN1 H163P mutation in a 
patient with early-onset Alzheimer’s disease: clinical, neuroimaging, and neuropathological findings. Neurosci 
Lett 2012, 530:109–114. 
77. Van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM: 
EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional 
cancer stem cell reporter. Stem Cells Transl Med 2013, 2:43–52. 
78. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, 
Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC: Polycomb protein EZH2 regulates 
tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate 
cancer. Cancer Res 2012, 72:3091–3104. 
79. Lee HW, Choe M: Expression of EZH2 in renal cell carcinoma as a novel prognostic marker. Pathol Int 
2012, 62:735–741. 
80. Banerjee R, Mani R-S, Russo N, Scanlon CS, Tsodikov A, Jing X, Cao Q, Palanisamy N, Metwally T, Inglehart 
RC, Tomlins S, Bradford C, Carey T, Wolf G, Kalyana-Sundaram S, Chinnaiyan AM, Varambally S, D’Silva NJ: 
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive 
squamous cell carcinoma. Oncogene 2011, 30:4339–4349. 
81. Liu J, Xie Y-S, Wang F-L, Zhang L-J, Zhang Y, Luo H-S: Cytotoxicity of 5-Aza-2’-deoxycytidine against 
gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of 
P16(INK4A). Biomed Pharmacother Biomédecine Pharmacothérapie 2013, 67:78–87. 
17 
Figure legends: 
Box symbol for Figure 1 and 2: 
 
 
 
 
 
Figure 1: Breast cancer and integrated Melanoma pathway landscape. The color node border 
indicates the common pathways among differentially expressed genes in two cancer cell lines: Green for 
down-regulated in both tumors; Dark red for up-regulated genes in both tumors; Blue for up/down-
regulated in BC and down in melanoma; Yellow for down-regulated in BC and up/down-regulated genes 
in melanoma; Orange for up-regulated and down-regulated genes in BC and melanoma, respectively and 
pink color for down-regulated and up-regulated genes in melanoma and BC, respectively. A) Enriched 
pathways among down- regulated genes in BC; B) Enriched pathways among up-regulated genes in 
BC. 
Figure 2: Melanoma and integrated Breast cancer pathway landscape. The color node border 
indicates the common pathways among differentially expressed genes in two cancer cell lines: Green for 
down-regulated in both tumors; Dark red for up-regulated genes in both tumors; Blue for up/down-
regulated in BC and down in melanoma; Yellow for down-regulated in BC and up/down-regulated genes 
in melanoma; Orange for up-regulated and down-regulated genes in BC and melanoma, respectively and 
pink color for down-regulated and up-regulated genes in melanoma and BC, respectively. A) Enriched 
pathways among down- regulated genes in melanoma. B) Enriched pathways among up-regulated 
genes in melanoma. 
Figure 3: The global network resulted from the union of transcriptional and post-transcriptional 
networks in MCF7. Node color: blue for up-regulated genes while yellow for down-regulated genes; 
Node border color:   dark brown indicates the significant TFs inhibited and blue for TF activated among 
differentially expressed genes (with p-value<0.05) and the non-colored nodes correspond to TFs that 
regulate at least one target of the epigenetically modified genes from TFactS analysis. 
Figure 4: The global network resulted from the union of transcriptional and post-transcriptional 
networks in A375. Node color: red for up-regulated genes while green for down-regulated genes; Node 
border color: green indicates the significant TFs inhibited and red for TF activated among differentially 
expressed genes (with p-value<0.05) and the non-colored nodes correspond to TFs that regulate at least 
one target of the epigenetically modified genes from TFactS analysis. 
Figure 5: The sub-network resulted from the intersection of regulatory map in MCF7 and A375: 
Node color: pink for up-regulated genes and light green for down-regulated genes common in two cancer 
cells, turquoise color to indicate genes up-regulated in BC and down-regulated in melanoma. Node border 
color: we used pink to show the common activated gene and brown if the TF is inhibited in one cell and 
activated in the other cell. We keep the same border color from figure 3 and 4 if TFs are common but are 
signifivantly enriched only in a specific cell lines. 
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Tables: 
Table 1: The common pathways associated to up-regulated genes. 
Type CCL Pathway name Genes p-value q-value 
BC Atm signaling ATM; MDM2; RBBP8; JUN; TP73 2.81E-06 7.96E-04 
Melanoma JUN; TP73 5.73E-03 3.42E-02 
BC Colorectal cancer JUN; TGFB3; RAF1; DCC 9.04E-03 6.89E-02 
Melanoma MSH2; JUN; DCC; TCF7L2 6.36E-04 1.45E-02 
BC DNA repair XPC; LIG3; ATM; TDG; ERCC6; FANCE; 
FANCC; RAD50 
1.30E-04 9.17E-03 
Melanoma MUTYH; POLD1; TDG; FANCA 5.94E-03 3.42E-02 
BC Extracellular matrix 
organization 
MMP14; TGFB3; ADAM17; CTSG; 
COL1A2; MMP8; CTSL2 
4.01E-03 5.02E-02 
Melanoma COL3A1; COL1A2; ITGB4; TIMP1; 
COL1A1 
2.78E-03 2.38E-02 
BC Hemostasis IGF2; PRKCH; PPP2R1B; TGFB3; AKAP1; 
SERPINC1; VAV2; PRKCE; ANGPT2; 
GNA12; GNA13; ABCC4; RAF1 
9.01E-03 6.89E-02 
Melanoma IGF2; TIMP1; SERPINC1; CD47; PRKCE; 
GRB7; PDPK1; ITPR3 
9.42E-03 4.30E-02 
BC Hippo signaling WNT2B; PPP2R1B; TGFB3; WNT1; ID2; 
TP73; TEAD4 
4.62E-03 5.02E-02 
Melanoma DVL3; LATS1; FZD4; TP73; TCF7L2 3.11E-03 2.50E-02 
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Table 2: The common pathways associated to down-regulated genes. 
Type CCL Pathway name Genes p-value q-value 
Melanoma Cytokine-cytokine 
receptor interaction* 
CSF2RB; IL2RA; TNFSF18; TNFSF15; IFNA1; IL13; 
IL4; IL12A; IFNB1; TNFRSF10B; BMPR1B; IFNA8; 
IFNA5; TNFRSF18; LIFR 
3.63E-11 4.24E-09 
BC IL2RA; IFNA8; IFNA1; BMPR1B; TNFSF8; IL2; IL26; 
TNFRSF18 
2.92E-04 1.61E-02 
Melanoma Jak-stat signaling 
pathway* 
CSF2RB; IL2RA; IFNA8; IFNA1; IL13; IFNA5; IFNB1; 
IL4; IL12A; LIFR 
3.09E-08 1.81E-06 
BC IL2RA; IFNA1; IFNA8; IL2; IL26 3.41E-03 6.86E-02 
Melanoma PI3K-AKT signaling 
pathway# 
IL2RA; IFNA8; IFNA1; IFNA5; IFNB1; IL4; FGF12; 
MDM2; FGF20 
2.11E-04 1.76E-03 
BC IL2RA; IFNA8; IFNA1; THBS2; RXRA; IL2; FGF12; 
TSC2; FGF20 
3.39E-04 1.61E-02 
Melanoma Nuclear receptor 
transcription pathway# 
NR1D1; AR; NR2E1 3.84E-03 1.36E-02 
BC NR1D1; NR2E1; RXRA; RORB 3.43E-04 1.61E-02 
Melanoma Autoimmune thyroid 
disease 
IL4; IFNA8; IFNA1; IFNA5 2.71E-04 1.98E-03 
BC IFNA1; IFNA8; IL2 4.56E-03 7.15E-02 
Some of the listed pathways are associated to up-regulated genes in BC (*) and in melanoma (#). 
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Table 3: The rest of common pathways associated to up or down-regulated genes in both cancer 
cell lines. 
Gene expression Pathway name Genes p-value q-value 
Up-BC P53 signaling pathway ATM; MDM2; PPM1D; APAF1; TP73 2.01E-03 4.56E-02 
Down-melanoma TNFRSF10B; MDM2; CASP8; BAI1 7.57E-04 4.12E-02 
Pathways in cancer CDKN2B; CEBPA; CASP8; AR; FGF12; MDM2; 
FGF20 
3.65E-03 1.33E-02 
Up-BC PGF; PTGS2; CEBPA; TGFB3; WNT1; JUN; DCC; 
STAT5B; CSF2RA; WNT2B; MDM2; RAF1; PAX8; 
IL8 
1.05E-04 9.17E-03 
Up-melanoma Regulation of insulin-like 
growth factor (IGF) 
transport and uptake by 
IGFBPs 
IGF2; IGFBP6 7.77E-03 4.09E-02 
Down-BC IGFBP1; MMP2 8.00E-03 9.59E-02 
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